Clinical Trial Update: Effect of Dapagliflozin on Electrocardiographic Parameters in Type 2 Diabetes Patients: DAPA - ECG Study [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial assessing the effect of dapagliflozin on electrocardiographic parameters in adults with Type 2 diabetes; the study is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiac Arrhythmia
• Type 2 Diabetes Mellitus

Drugs mentioned

• FARXIGA (dapagliflozin)

Snippet

Sponsor: Beneficência Portuguesa de São Paulo | Conditions: Arrhythmias, Cardiac, Diabetes Mellitus | Phase 4 | Status: COMPLETED